Drug Profile
Research programme: diabetes and obesity therapies - Handok Pharmaceuticals
Alternative Names: HL 1515; HL 3715; HL 5201Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Handok Inc
- Class Obesity therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Diabetes mellitus in South Korea (unspecified route) (Handok pipeline, March 2023)
- 28 Mar 2023 Discontinued - Preclinical for Obesity in South Korea (unspecified route) (Handok pipeline, March 2023)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Diabetes-mellitus in South Korea